Pharming Group NV 2014 AR2
The report highlights Pharming Group N.V.'s significant transitions in 2014, including the FDA approval and subsequent US launch of its lead product, Ruconest, for Hereditary Angioedema (HAE). Financially, the company experienced a substantial revenue increase to €21.2 million, driven by a US$20.0 million milestone payment from partner Salix Pharmaceuticals. Pharming also expanded its pipeline by acquiring assets from Transgenic Rabbit Models, adding new Enzyme Replacement Therapy leads. Additionally, the company initiated direct commercialisation of Ruconest in Austria, Germany, and the Netherlands, and commenced a Phase II clinical trial for HAE prophylaxis.
Company: Pharming Group NV
Sector: Manufacturing
Country: Netherlands
Year: 2014
Type: AR2
Pages: 108
Back to company
Pharming Group NV
Annual Report
The report highlights Pharming Group N.V.'s significant transitions in 2014, including the FDA approval and subsequent US launch of its lead product, Ruconest, for Hereditary Angioedema (HAE). Financially, the company experienced a substantial revenue increase to €21.2 million, driven by a US$20.0 million milestone payment from partner Salix Pharmaceuticals. Pharming also expanded its pipeline by acquiring assets from Transgenic Rabbit Models, adding new Enzyme Replacement Therapy leads. Additionally, the company initiated direct commercialisation of Ruconest in Austria, Germany, and the Netherlands, and commenced a Phase II clinical trial for HAE prophylaxis.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2014
Reporting Period
Jan 1, 2014 - Dec 31, 2014
Fiscal Year
2014
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women in Management
Employees